MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →

DocGo Stock

DocGo Inc.

DCGONASDAQMarkt
US$0.27
-3.7% today

Company data

Sector
Healthcare
Industry
Medical - Care Facilities
Country
United States
CEO
Lee Bienstock
Employees
3,568
Market cap
$27 M
IPO
17/12/2020

DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emergency response, alongside routine non-emergency transfers facilitated…

DocGo stock: price history

16/10/25-77.7 %16/10/26

1D

-3.7%

1W

-19.7%

1M

-28.7%

6M

-58.1%

YTD

-69.1%

1Y

-77.7%

2Y

-92.0%

5Y

-97.3%

10Y

–

Next earnings date

Next earnings date

09/11/2026 (in 23 days)

Volatility around earnings

~100% stronger price swings than usual

Pattern chart

Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta

What does this mean?

Volatility squeeze

Bearish

Price swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.

Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.

Ask the agents about DocGo

Analyst assessment of DocGo

PRICE TARGET LOW

US$1.50

CONSENSUS

US$5.84

MEDIAN

US$5.43

PRICE TARGET HIGH

US$11.00

0

STRONG BUY

7

BUY

1

HOLD

0

SELL

0

STRONG SELL

8

TOTAL · Buy

As of: 30/09/2026

ANALYST FIRMRATINGACTIONDATE
NeedhamBuymaintain30/09/2026
Canaccord GenuityHoldmaintain18/08/2026
NeedhamBuymaintain18/08/2026
Canaccord GenuityHoldmaintain25/03/2026
Cantor FitzgeraldOverweightmaintain17/03/2026
NeedhamBuymaintain17/03/2026
StifelBuymaintain17/03/2026
Canaccord GenuityHoldmaintain12/11/2025

DocGo stock metrics

P/E

-0.14

P/B

0.23

EV/EBITDA

-0.17

RETURN ON EQUITY

-13.3%

NET MARGIN

-21.5%

DEBT/EQUITY

0.22

DIVIDEND YIELD

0.0%

AS OF

30/06/2026

Free float & liquidity

FREE FLOAT

97.1%

FLOAT SHARES

96,121,771

AVG. DAILY VOLUME (30D)

643,521

Insider transactions (SEC)

ROLETRANSACTIONSHARESPRICEPLAN TYPEDATE

Bienstock Lee

OfficerTax settlement15,6440.59Spontaneous14/05/2026

Institutional holders

FUND / INSTITUTIONSHARESCHANGEAS OF
Wealth Enhancement Trust Services, Inc.0-5330/09/2026
Marquette Asset Management, LLC0-338,34430/09/2026
VANGUARD CAPITAL MANAGEMENT LLC3,728,207+45,63930/06/2026
P.A.W. CAPITAL CORP3,505,000+500,00030/06/2026
Knott David M Jr2,670,850+030/06/2026
Page 1 / 3

Comparable stocks

Frequently asked questions about DocGo stock

What does DocGo do?

DocGo Inc. is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in United States.

The CEO is Lee Bienstock, the company employs around 3,568 people.

The IPO was on 17/12/2020; the stock trades on NASDAQ under the ticker DCGO.

What do analysts say about DocGo stock?

8 analysts rate the stock, the consensus is Buy (as of 30/09/2026).

The average price target is US$5.84, ranging from US$1.50 to US$11.00, with a median of US$5.43.

This is an external assessment, not a statement by Market Jury.

When does DocGo report next?

The next earnings date is 09/11/2026.

Around past earnings, price swings were roughly 100% stronger than usual.

Does DocGo pay a dividend?

No, DocGo currently does not pay a dividend.

Which stocks are comparable to DocGo?

Comparable stocks include HCA Healthcare, Tenet Healthcare, DaVita, Universal Health Services, Hims & Hers Health, LifeStance Health Group, Concentra Group Holdings Parent and Acadia Healthcare Company.

How can I get DocGo stock analyzed?

Clicking "Analyze stock" lets five strategies assess DocGo against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.